These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 38007466)
1. The survivin-ran inhibitor LLP-3 decreases oxidative phosphorylation, glycolysis and growth of neuroblastoma cells. Galiger C; Zohora FT; Dorneburg C; Tews D; Debatin KM; Beltinger C BMC Cancer; 2023 Nov; 23(1):1148. PubMed ID: 38007466 [TBL] [Abstract][Full Text] [Related]
2. Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex. Guvenc H; Pavlyukov MS; Joshi K; Kurt H; Banasavadi-Siddegowda YK; Mao P; Hong C; Yamada R; Kwon CH; Bhasin D; Chettiar S; Kitange G; Park IH; Sarkaria JN; Li C; Shakhparonov MI; Nakano I Clin Cancer Res; 2013 Feb; 19(3):631-42. PubMed ID: 23251006 [TBL] [Abstract][Full Text] [Related]
3. LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis. Dorneburg C; Fischer M; Barth TFE; Mueller-Klieser W; Hero B; Gecht J; Carter DR; de Preter K; Mayer B; Christner L; Speleman F; Marshall GM; Debatin KM; Beltinger C Clin Cancer Res; 2018 Nov; 24(22):5772-5783. PubMed ID: 29925504 [No Abstract] [Full Text] [Related]
4. Therapeutic targeting of YY1/MZF1 axis by MZF1-uPEP inhibits aerobic glycolysis and neuroblastoma progression. Fang E; Wang X; Wang J; Hu A; Song H; Yang F; Li D; Xiao W; Chen Y; Guo Y; Liu Y; Li H; Huang K; Zheng L; Tong Q Theranostics; 2020; 10(4):1555-1571. PubMed ID: 32042322 [TBL] [Abstract][Full Text] [Related]
5. FUBP1 promotes neuroblastoma proliferation via enhancing glycolysis-a new possible marker of malignancy for neuroblastoma. Jiang P; Huang M; Qi W; Wang F; Yang T; Gao T; Luo C; Deng J; Yang Z; Zhou T; Zou Y; Gao G; Yang X J Exp Clin Cancer Res; 2019 Sep; 38(1):400. PubMed ID: 31511046 [TBL] [Abstract][Full Text] [Related]
6. The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma. Azuhata T; Scott D; Takamizawa S; Wen J; Davidoff A; Fukuzawa M; Sandler A J Pediatr Surg; 2001 Dec; 36(12):1785-91. PubMed ID: 11733907 [TBL] [Abstract][Full Text] [Related]
7. BIRC5/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma. Hagenbuchner J; Kiechl-Kohlendorfer U; Obexer P; Ausserlechner MJ Oncogene; 2016 Apr; 35(16):2052-61. PubMed ID: 26148234 [TBL] [Abstract][Full Text] [Related]
8. Significance of survivin mRNA expression in prognosis of neuroblastoma. Ito R; Asami S; Motohashi S; Ootsuka S; Yamaguchi Y; Chin M; Shichino H; Yoshida Y; Nemoto N; Mugishima H; Suzuki T Biol Pharm Bull; 2005 Apr; 28(4):565-8. PubMed ID: 15802787 [TBL] [Abstract][Full Text] [Related]
9. Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro. Kunnimalaiyaan S; Schwartz VK; Jackson IA; Clark Gamblin T; Kunnimalaiyaan M BMC Cancer; 2018 May; 18(1):560. PubMed ID: 29751783 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms of neuroblastoma cell growth inhibition by CARP-1 functional mimetics. Muthu M; Cheriyan VT; Munie S; Levi E; Frank J; Ashour AE; Singh M; Rishi AK PLoS One; 2014; 9(7):e102567. PubMed ID: 25033461 [TBL] [Abstract][Full Text] [Related]
12. HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression. Song H; Li D; Wang X; Fang E; Yang F; Hu A; Wang J; Guo Y; Liu Y; Li H; Chen Y; Huang K; Zheng L; Tong Q J Hematol Oncol; 2020 Mar; 13(1):24. PubMed ID: 32216806 [TBL] [Abstract][Full Text] [Related]
13. BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery. Hagenbuchner J; Kuznetsov AV; Obexer P; Ausserlechner MJ Oncogene; 2013 Oct; 32(40):4748-57. PubMed ID: 23146905 [TBL] [Abstract][Full Text] [Related]
14. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma. Maser T; Zagorski J; Kelly S; Ostrander A; Goodyke A; Nagulapally A; Bond J; Park Y; Saulnier Sholler G Cancer Med; 2020 Nov; 9(21):8144-8158. PubMed ID: 33034426 [TBL] [Abstract][Full Text] [Related]
15. Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma. Azuhata T; Scott D; Griffith TS; Miller M; Sandler AD J Pediatr Surg; 2006 Aug; 41(8):1431-40. PubMed ID: 16863850 [TBL] [Abstract][Full Text] [Related]
16. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma. Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342 [TBL] [Abstract][Full Text] [Related]
17. [Role and mechanism of cysteine and glycine-rich protein 2 in the malignant progression of neuroblastoma]. Zhang Y; Guo J; Zhan S; Hong E; Yang H; Jia A; Chang Y; Guo Y; Zhang X Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Jun; 56(3):495-504. PubMed ID: 38864136 [TBL] [Abstract][Full Text] [Related]
18. The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention. Peirce SK; Findley HW; Prince C; Dasgupta A; Cooper T; Durden DL Cancer Chemother Pharmacol; 2011 Aug; 68(2):325-35. PubMed ID: 20972874 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway. Chen Y; Tsai YH; Tseng SH Surgery; 2013 Jan; 153(1):4-16. PubMed ID: 22703967 [TBL] [Abstract][Full Text] [Related]
20. Survivin knockdown increased anti-cancer effects of (-)-epigallocatechin-3-gallate in human malignant neuroblastoma SK-N-BE2 and SH-SY5Y cells. Hossain MM; Banik NL; Ray SK Exp Cell Res; 2012 Aug; 318(13):1597-610. PubMed ID: 22507272 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]